PMV Pharma Q2 net loss $21.2M; cash $148.3M; Phase 2 interim analysis webinar Sept 10

PMV Pharmaceuticals, Inc.

2025-Q2 EPS reported -$0.74 vs consensus -$0.39 ▼ miss (-89.3%)

Net loss $21.2M for Q2 2025 vs $1.2M in Q2 2024, due to prior-year $16.2M tax benefit from NOL sale.
Cash, equivalents, and marketable securities $148.3M as of June 30, 2025, expected runway to end of 2026.
R&D expenses $18.4M (up 26% YoY) driven by contractual research costs for rezatapopt program.
Investor webinar Sept 10 to review Phase 2 PYNNACLE interim data; ~65 patients, ~45% ovarian cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.